T2 Biosystems is an in vitro diagnostics company and engaged in the detection of sepsis-causing pathogens and antibiotic resistance genes. Co.'s products include: T2Dx® Instrument, which runs diagnostic tests from patient samples; T2Candida® Panel, which is a direct-from-blood test that identifies the lethal form of blood stream infections that cause sepsis candidemia; T2Bacteria® Panel, which is a direct-from-blood test that detects bacterial pathogens associated with sepsis; T2Resistance® Panel, which is a direct-from-blood test that detects resistance genes from both gram-positive and gram-negative pathogens; and T2SARS-CoV-2 Panel, which detect SARS-CoV-2, the coronavirus in patients. The TTOO stock yearly return is shown above.
The yearly return on the TTOO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TTOO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|